Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

BACKGROUND: Lymphedema is an incurable disease associated with lymphatic dysfunction that causes tissue swelling and fibrosis ...

Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to ...

The therapeutic interventions by VEGFR antagonist axitinib or exogenous IL-3 can reestablish the IL-3/IL-3Rα crosstalk, reducing astrocytes and microglia activation, LDs accumulation and ...

U.S. stocks staged a comeback on Friday, with the S&P 500 surging 1.59% and reversing a sharp sell-off driven by fears that ...